The effects and efficacy of garadacimab-ANDEMBRY

Garadacimab (garadacimab)-ANDEMBRY is a preventive treatment for hereditary angioedema (HAE) that has received great attention in recent years. It is suitable for adults and adolescents aged 12 years and above with HAE to reduce the risk of recurrent attacks. The drug is administered by subcutaneous injection once a month. Patients can inject it themselves after professional training, or they can be assisted by family members or medical staff. It is highly convenient to use and suitable for long-term management.

The mechanism of action of gadaximab revolves around HAE's key pathogenic pathway - the "contact system activation" link. Studies have shown that the main cause of HAE is an abnormal increase in the level of bradykinin in the body. Excessive release of bradykinin can lead to increased vascular permeability, causing typical symptoms of skin, throat and abdominal edema. The target of Gadaximab is activating factor XII (FXIIa), which is in the starting position in the contact system. Once activated, it will gradually trigger the conversion of prekallikrein to kallikrein, ultimately promoting the production of bradykinin.

By selectively inhibiting FXIIa, Gadaximab can effectively block the above cascade reaction, prevent bradykinin from abnormally increasing, and reduce the inflammatory response and vasodilation from the source, thereby achieving the purpose of preventing HAE attacks. Because of its upstream site of action, precision, and deep intervention, gadaximabis considered to be a representative monoclonal antibody drug in the FXIIa inhibitor category.

Overall, the emergence of gadaximab provides a more stable, sustainable and easy-to-manage biologic option for patients who need long-term control of HAE attacks. Its monthly dosing frequency, clear target mechanism, and excellent preventive effect make it occupy an increasingly important position in modern HAE management programs, especially for patients who want to reduce the burden of attacks and improve quality of life as one of the long-term treatment strategies.

Reference materials:https://www.andembryhcp.com/